National trends in heart failure and hyperlipidemia related mortality in the United States, 1999–2024 Authors: Biruk Demisse Ayalew, David N. Smith, Laksh Kumar, Muhammad Umar, Talha Ali, Sahil Jairamani, Adarsh Raja, Ibrahim Khalil, Mirza Mohammad Ali Baig Published: 2026 ABSTRACT Cardiovascular disease remains the leading cause of death in the United States, with heart failure (HF) and hyperlipidemia substantially contributing to mortality. This study aimed to examine national trends in HF-related mortality with coexisting hyperlipidemia from 1999 to 2024 and project future mortality patterns through 2035. Mortality data were obtained from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database. Deaths were identified when heart failure and hyperlipidemia were listed on death certificates using the International Classification of Diseases, Tenth Revision (ICD-10) codes. Age-adjusted mortality rates (AAMRs) were calculated using the 2000 U.S. standard population and were stratified by sex, race/ethnicity, census region, and urbanization level. Temporal trends were evaluated using joinpoint regression analysis. Forecasts for 2025–2035 were generated using machine learning-based Seasonal Autoregressive Integrated Moving Average (SARIMA) time-series models. From 1999 to 2024, 283,161 deaths involving HF with hyperlipidemia were recorded on death certificates. The AAMR increased from 0.7 to 6.8 per 100,000 population, with a notable increase after 2018. Mortality rates were higher among men than women and were elevated in the non-Hispanic Black and American Indian/Alaska Native populations. Higher rates were also observed in nonmetropolitan counties and in the Midwest and West regions of the United States. Mortality involving HF with hyperlipidemia has increased over the past two decades, with persistent demographic and geographic differences. These findings highlight the importance of continued surveillance and targeted prevention strategies to address the cardiovascular health disparities in the United States. 1. Introduction In the US, cardiovascular disease continues to be the leading cause of mortality.[1] The 3 major modifiable risk factors are smoking, high blood pressure, and elevated serum cholesterol levels.[2] Atherosclerotic cardiovascular disease (ASCVD) is largely caused by serum cholesterol and the lipoproteins that carry it.[3] All ranges of left ventricular ejection fraction are associated with atherosclerotic cardiovascular disease, which is often associated with heart failure (HF), a prevalent disorder with an estimated prevalence of 1–2% in the Western world.[4] These illnesses are linked to higher mortality rates and play a role in both non cardiovascular and cardiovascular deaths.[5] Despite treatment for heart failure, 30–40% of patients die within a year of diagnosis, and 60–70% die within 5 years.[6]It accounts for approximately 5% of medical admissions and complicates an additional 10–15% of cases.[7] According to retrospective analyses and reevaluations of statin studies, statins may be beneficial for patients with HF with both ischemic and nonischemic etiologies.[8] Better results may be due to their antioxidant properties, which include lowering nicotinamide adenine dinucleotide phosphate dependent superoxide production.[9] Hyperlipidemia may also contribute to the development and progression of heart failure through several biological mechanisms.[10] In addition, lipid abnormalities are associated with endothelial dysfunction, systemic inflammation, and oxidative stress, all of which may contribute to adverse cardiac remodeling and reduced myocardial contractility.[11] Together, these mechanisms suggest that abnormal lipid metabolism may play a significant role in the progression of cardiovascular risk factors to overt heart failure. Therefore, our study aimed to examine the national trends in heart failure and hyperlipidemia-related mortality in the United States from 1999 to 2024, with a particular focus on demographic and regional disparities. Furthermore, we sought to project future mortality trends through 2035 using time-series modeling to better understand the potential trajectory of this growing public health concern and to inform long-term preventive and policy strategies. In accordance with the TITAN Guidelines 2025 for the transparent use of AI in scholarly communication, no artificial intelligence (AI) tools were used in the research design, data collection, analysis, or interpretation; instead, AI support was limited to improving the language during manuscript preparation.[12] 2. Method 2.1. Choosing the characteristics and population Mortality certificate data for this comprehensive study were sourced from the Wide Ranging Online Data for Epidemiologic Research (CDC WONDER) database of the Centers for Disease Control and Prevention (CDC).[13] Deaths were identified when hyperlipidemia (ICD-10 code E78) and heart failure–related conditions were listed as the causes of death on the death certificate. Heart failure–related codes included I50 (heart failure), I11.0 (hypertensive heart disease with heart failure), I13.0 (hypertensive heart and renal disease with heart failure), and I13.2 (hypertensive heart and renal disease with both heart and renal failure) (Table S9, Supplemental Digital Content 1). These codes were selected to capture deaths involving heart failure across clinically related diagnostic categories that are commonly used in mortality surveillance. Data on the causes of death from death certificates from all 50 states and the District of Columbia were included in the dataset. The Multiple Causes of Death Public Use Registry death records were examined to identify instances in which heart failure linked to hyperlipidemia was either the primary cause of death or a contributing factor to death. Participants were grouped according to age, which ranged from less than a year old to 85 years or older at the time of death. Since this study made use of publicly available anonymized government data, regional institutional review board approval was not necessary. This study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.[14] 2.2. Gathering of data The information set contained population counts, year of death, site of death, urban/rural classifications, demographic and geographic features, and state-specific statistics. Hospitals, nursing homes, long-term care facilities, hospices, and private homes were among the places where people died. Race, ethnicity, age, and sex were the only demographic factors. Asian or Pacific Islander, Hispanic or Latino, American Indian or Alaska Native, Black or African American, and White were the racial and ethnic categories. The National Center for Health Statistics Urban–Rural Classification Scheme was used to establish whether an area was urban or rural. Medium/small metropolitan areas with populations of 50,000–999,999 and large metropolitan regions with populations of one million or more were considered urban areas. The 2013 U.S. Census classified counties as rural if they had fewer than 50,000 residents.[15] Geographic regions were classified according to the U.S. Census Bureau criteria into 4 major groups: Northeast, Midwest, South, and West.[16] 2.3. The statistical method analysis To assess mortality trends from 1999 to 2024, age-adjusted mortality rates (AAMRs) and crude mortality rates (CMRs) per 100,000 population were calculated, along with 95% confidence intervals (CIs). Age adjustment was performed using the U.S. standard population from 2000 to allow comparisons across demographic groups and time periods.[17] Mortality rates were categorized by census region or state, race/ethnicity, sex, year, and urbanization. Joinpoint regression analysis was performed using the Joinpoint Regression Program (version 5.4.0., National Cancer Institute) to identify statistically significant changes in mortality patterns over time.[18] For each demographic variable, Annual Percentage Changes (APCs) and related 95% CIs were significant if the 95% CI excluded zero and the P-value was <.05. Microsoft Excel was used to create figures. 2.4. SARIMA forecasting Time series forecasting was performed using Seasonal Auto Regressive Integrated Moving Average (SARIMA) models, implemented in R (version 4.3.2).[19] Annual ASMRs from 1999 to 2024 were extracted from the CDC WONDER Multiple Cause of Death database and age-standardized to the 2000 U.S. standard population. The data were stratified by sex and overall. Each series underwent a stationarity assessment via augmented Dickey-Fuller tests and visual inspection of autocorrelation (ACF) and partial autocorrelation (PACF) plots. First-order differencing (d = 1) achieved stationarity in all series, and no seasonal component was detectable in the annual data (D = 0). Model identification proceeded iteratively: candidate SARIMA(p,d,q) structures were evaluated using the Akaike Information Criterion (AICc), with p and q ranging from 0 to 2. The optimal overall model was SARIMA(1,1,1); for females, SARIMA(2,1,1); and for males, SARIMA(1,1,2). The Ljung-Box test confirmed the absence of residual autocorrelation (P > .05). The normality of the residuals was verified using Shapiro–Wilk tests and quantile-quantile (QQ) plots. Forecasts were generated for 2025–2035 using the fitted models, with 95% prediction intervals derived from empirical distributions of forecast errors. The average annual percent change (AAPC) and its confidence bounds were computed via loglinear regression of forecasted values: ln (ASMR) = β0 + β1·t, where t = year—2025, and AAPC = (e^{β1}–1) × 100%. Confidence intervals for the AAPC were obtained by applying the same regression to lower and upper prediction bounds. All models satisfied the diagnostic criteria, with mean absolute percentage errors in one-step-ahead validation below 3.2%. 3. Results Between 1999 and 2024, 283,161 deaths were attributed to heart failure and hyperlipidemia in the United States. Of these, 135,702 (47.9%) occurred in women and 147,459 (52.1%) in men, indicating a modest male predominance. Regarding the place of death, the largest proportion occurred at the decedent’s home (102,791; 36.3%), followed by medical facilities (91,951; 32.5%) and nursing home/long term care facilities (62,803; 22.2%). A smaller fraction of deaths occurred in hospice settings (12,334; 4.4%). Tables S1 and S2, Supplemental Digital Content 2. 3.1. Overall trends Between 1999 and 2024, the overall age-adjusted mortality rate (AAMR) of heart failure–related deaths with hyperlipidemia was 2.9 per 100,000 (95% CI, 2.8–2.9). The AAMR increased from 0.7 (95% CI, 0.7–0.7) in 1999 to 1.7 (95% CI, 1.6–1.7) in 2005, corresponding to a significant annual increase (APC, 15.50%; 95% CI, 11.94–22.17; P < .001). From 2005 to 2018, mortality continued to rise to 3.6 (95% CI, 3.6–3.7) with an APC of 5.66% (95% CI, 5.05–6.14; P < .001). Between 2018 and 2021, the AAMR increased from 3.6 (95% CI, 3.6–3.7) to 5.7 (95% CI, 5.6–5.7), corresponding to an APC of 17.40% (95% CI, 14.91–18.88; P < .001). From 2021 to 2024, mortality continued to increase to 6.8 (95% CI, 6.7–6.9) with an APC of 5.79% (95% CI, 4.50–7.04; P < .001). These temporal trends are illustrated in Figure 1 and are detailed in Tables S3 and S4, Supplemental Digital Content 3. Age-adjusted mortality rates (AAMR) for hyperlipidemia-related and heart failure-related deaths in the United States from 1999 to 2024, stratified by sex/gender. 3.2. Sex From 1999 to 2024, the overall AAMR was 3.6 per 100,000 (95% CI, 3.6–3.7) among men and 2.3 per 100,000 (95% CI, 2.3–2.4) among women. 3.3. Women Among women, the AAMR increased from 0.6 (95% CI, 0.5–0.6) in 1999 to 1.4 (95% CI, 1.3–1.4) in 2005, corresponding to an APC of 15.61% (95% CI, 11.39–25.03; P = .004). From 2005 to 2018, mortality rose to 2.9 (95% CI, 2.8–2.9) with an APC of 5.46% (95% CI, 4.42–6.10; P = .008). Between 2018 and 2021, the AAMR increased to 4.5 (95% CI, 4.4–4.6) with an APC of 16.86% (95% CI, 13.48–18.81; P < .001). From 2021 to 2024, the rate increased further to 5.5 (95% CI, 5.4–5.6) with an APC of 6.61% (95% CI, 4.32–8.07; P < .001). 3.4. Men Among men, the AAMR increased from 0.8 (95% CI, 0.8–0.9) in 1999 to 2.1 (95% CI, 2.0–2.1) in 2005 (APC, 16.75%; 95% CI, 13.32–22.85; P < .001). From 2005 to 2017, mortality increased to 4.2 (95% CI, 4.1–4.3) with an APC of 5.43% (95% CI, 4.68–6.01; P < .001). Between 2017 and 2021, the AAMR increased to 7.2 (95% CI, 7.1–7.4) (APC, 14.38%; 95% CI, 12.72–17.11; P < .001). From 2021 to 2024, mortality increased further to 8.5 (95% CI, 8.4–8.6) with an APC of 6.08% (95% CI, 4.58–7.64; P < .001). These sex-specific trends are shown in Figure 1 and Tables S3 and S4, Supplemental Digital Content 3. 3.5. Race and ethnicity Between 1999 and 2024, differences in mortality rates were observed across racial and ethnic groups. The overall AAMR was highest among Non-Hispanic Black individuals (3.1; 95% CI, 3.0–3.3), American Indian or Alaska Native individuals (3.0; 95% CI, 2.4–4.2), and Non-Hispanic White populations (3.0; 95% CI, 2.9–3.1). Lower rates were observed among Hispanic or Latino populations (2.2; 95% CI, 2.0–2.4) and Asian or Pacific Islander populations (1.7; 95% CI, 1.5–1.9). 3.6. American Indian or Alaska native Among American Indian or Alaska Native individuals, the AAMR increased from 3.3 (95% CI, 2.4–4.4) in 2009 to 6.3 (95% CI, 5.3–7.2) in 2024 (APC, 5.66%; 95% CI, 3.58–8.76; P < .001). 3.7. Asian or Pacific islander Among Asian or Pacific Islander individuals, the AAMR increased from 0.5 (95% CI, 0.4–0.8) in 1999 to 1.5 (95% CI, 1.2–1.8) in 2007 (APC, 11.69%; 95% CI, 6.65–39.68; P = .0072). From 2007 to 2015, rates remained stable at approximately 1.6 (95% CI, 1.4–1.8) (APC, 1.90%; 95% CI, −5.24 to 8.46; P = .67). Thereafter, mortality increased to 3.6 (95% CI, 3.3–3.8) in 2024 (APC, 9.07%; 95% CI, 7.32–13.11; P = .002). 3.8. Non-Hispanic black Among Non-Hispanic Black individuals, mortality increased from 0.5 (95% CI, 0.4–0.6) in 1999 to 2.1 (95% CI, 1.9–2.2) in 2008 (APC, 13.33%; 95% CI, 9.80–25.47; P = .002). From 2008 to 2018, the AAMR increased to 3.8 (95% CI, 3.6–4.0) (APC, 6.04%; 95% CI, 1.82–7.16; P = .016). Between 2018 and 2021, rates increased to 6.4 (95% CI, 6.2–6.7) (APC, 19.35%; 95% CI, 14.84–22.24; P < .001). From 2021 to 2024, mortality increased to 7.9 (95% CI, 7.6–8.2) (APC, 6.23%; 95% CI, 1.95–8.51; P = .004). 3.9. Non-Hispanic white Among Non-Hispanic White populations, the AAMR increased from 0.7 (95% CI, 0.7–0.8) in 1999 to 1.7 (95% CI, 1.6–1.7) in 2005 (APC, 15.04%; 95% CI, 11.58–21.32; P < .001). From 2005 to 2018, mortality increased to 3.8 (95% CI, 3.7–3.8) (APC, 5.75%; 95% CI, 5.13–6.24; P < .001). Between 2018 and 2021, rates increased to 5.9 (95% CI, 5.8–6.0) (APC, 17.43%; 95% CI, 15.08–18.91; P < .001). From 2021 to 2024, mortality increased to 7.1 (95% CI, 7.0–7.2) (APC, 6.19%; 95% CI, 4.91–7.40; P < .001). 3.10. Hispanic or Latino Among Hispanic or Latino populations, the AAMR increased from 0.6 (95% CI, 0.5–0.7) in 1999 to 1.5 (95% CI, 1.3–1.6) in 2006 (APC, 13.53%; 95% CI, 8.08–41.94; P = .0016). From 2006 to 2017, rates were approximately 2.6 (95% CI, 2.4–2.8) (APC, 4.68%; 95% CI, 2.94–5.99; P = .12). Between 2017 and 2020, mortality increased to 4.1 (95% CI, 3.9–4.3) (APC, 19.08%; 95% CI, 12.95–23.45; P = .004). From 2020 to 2024, the AAMR increased to 4.9 (95% CI, 4.7–5.2) (APC, 5.16%; 95% CI, 1.58–7.12; P = .019). These trends are shown in Figure 2 and Tables S3–S5, Supplemental Digital Content 3. Age-adjusted mortality rates (AAMR) for hyperlipidemia-related and heart failure-related deaths in the United States from 1999 to 2024, stratified by race/ethnicity. 3.11. Census region Geographic differences were observed across U.S. census regions. Overall AAMR was highest in the West (3.2; 95% CI, 3.1–3.3), followed by the Midwest (3.0; 95% CI, 3.0–3.2) and the South (2.9; 95% CI, 2.8–3.0), while the Northeast had the lowest rate (2.4; 95% CI, 2.3–2.5). Regional temporal trends are summarized below: 3.12. Northeast AAMR increased from 0.5 (95% CI, 0.5–0.6) in 1999 to 1.2 (95% CI, 1.1–1.3) in 2005 (APC, 15.67%; 95% CI, 9.38–43.20; P = .0048). From 2005 to 2018, rates increased to 3.0 (95% CI, 2.9–3.1) (APC, 7.12%; 95% CI, 3.11–7.94; P = .006). Between 2018 and 2021, the AAMR increased to 4.9 (95% CI, 4.8–5.1) (APC, 18.65%; 95% CI, 14.24–21.38; P < .001). From 2021 to 2024, mortality increased to 5.7 (95% CI, 5.5–5.9) (APC, 4.18%; 95% CI, 0.28–6.38; P = .0432). 3.13. Midwest AAMR increased from 0.8 (95% CI, 0.8–0.9) in 1999 to 2.0 (95% CI, 1.9–2.1) in 2005 (APC, 16.56%; 95% CI, 10.79–33.47; P < .001). From 2005 to 2015, mortality increased to 3.2 (95% CI, 3.1–3.4) (APC, 4.65%; 95% CI, −1.26 to 6.15; P = .0832). Between 2015 and 2024, the AAMR increased to 6.8 (95% CI, 6.6–6.9) (APC, 8.92%; 95% CI, 8.05–10.62; P < .001). 3.14. South AAMR increased from 0.6 (95% CI, 0.6–0.7) in 1999 to 1.3 (95% CI, 1.2–1.3) in 2003 (APC, 21.58%; 95% CI, 14.79–38.29; P < .001). From 2003 to 2017, mortality increased to 3.2 (95% CI, 3.1–3.3) (APC, 6.15%; 95% CI, 5.51–6.70; P < .001). Between 2017 and 2021, rates increased to 5.9 (95% CI, 5.8–6.1) (APC, 17.11%; 95% CI, 15.59–19.40; P < .001). From 2021 to 2024, mortality increased to 7.4 (95% CI, 7.3–7.6) (APC, 7.55%; 95% CI, 6.28–8.78; P < .001). 3.15. West AAMR increased from 0.8 (95% CI, 0.8–0.9) in 1999 to 2.3 (95% CI, 2.2–2.4) in 2006 (APC, 15.14%; 95% CI, 11.54–21.80; P = .002). From 2006 to 2018, mortality increased to 3.9 (95% CI, 3.7–4.0) (APC, 4.03%; 95% CI, 2.78–4.80; P = .0016). Between 2018 and 2021, the AAMR increased to 6.0 (95% CI, 5.8–6.1) (APC, 14.29%; 95% CI, 10.48–16.58; P = .0004). From 2021 to 2024, mortality increased to 6.7 (95% CI, 6.5–6.8) (APC, 4.76%; 95% CI, 1.09–6.72; P = .0188). These regional patterns are presented in Figure 3 and Tables S3–S6, Supplemental Digital Content 3. Age-adjusted mortality rates (AAMR) for hyperlipidemia-related and heart failure-related deaths in the United States from 1999 to 2024, stratified by Census Region. 3.16. Urbanization Mortality rates were consistently higher in nonmetropolitan counties than in metropolitan counties. Between 1999 and 2020, the overall AAMR was 3.0 per 100,000 (95% CI, 3.0–3.0) in nonmetropolitan areas and 2.3 per 100,000 (95% CI, 2.3–2.3) in metropolitan areas. In metropolitan counties, the AAMR increased from 0.7 (95% CI, 0.6–0.7) in 1999 to 1.6 (95% CI, 1.6–1.7) in 2005 (APC, 15.23%; 95% CI, 11.88–21.87; P < .001). From 2005 to 2018, mortality increased to 3.4 (95% CI, 3.4–3.5) (APC, 5.64%; 95% CI, 4.84–6.16; P < .001). Between 2018 and 2020, the AAMR increased to 4.7 (95% CI, 4.6–4.8) (APC, 18.04%; 95% CI, 14.04–20.58; P < .001). In nonmetropolitan counties, mortality increased from 0.8 (95% CI, 0.7–0.9) in 1999 to 2.2 (95% CI, 2.0–2.3) in 2006 (APC, 14.88%; 95% CI, 11.92–20.60; P < .001). From 2006 to 2017, the AAMR increased to 4.2 (95% CI, 4.0–4.3) (APC, 5.52%; 95% CI, 4.28–6.29; P = .0016). Between 2017 and 2020, mortality increased to 6.4 (95% CI, 6.2–6.6) (APC, 15.03%; 95% CI, 12.15–20.19; P < .001). The findings are presented in Figure 4 and Tables S3–S7, Supplemental Digital Content 3. Age-adjusted mortality rates (AAMR) for hyperlipidemia-related and heart failure-related deaths in the United States from 1999 to 2020, stratified by urbanization. 3.17. State-level variation Substantial variation was observed across the U.S. states. The highest AAMRs were reported in Vermont (6.61; 95% CI, 6.12–7.02), Nebraska (4.65; 95% CI, 4.48–4.92), North Dakota (4.43; 95% CI, 4.14–4.81), South Dakota (4.39; 95% CI, 4.07–4.70), and Iowa (4.36; 95% CI, 4.12–4.51). The lowest AAMRs were observed in Massachusetts (1.46; 95% CI, 1.35–1.49), Connecticut (1.55; 95% CI, 1.52–1.67), Georgia (1.61; 95% CI, 1.51–1.64), Alaska (1.78; 95% CI, 1.42–2.15), and Illinois (1.85; 95% CI, 1.75–1.86). These results are illustrated in Figure 5 and are presented in Table S8, Supplemental Digital Content 4. Age-adjusted mortality rates (AAMR) for hyperlipidemia-related and heart failure-related deaths in the United States from 1999 to 2024, stratified by state. 3.18. Forecast analysis Age-standardized mortality rates (ASMRs) for heart failure with comorbid hyperlipidemia in the United States, derived from data obtained through the Centers for Disease Control and Prevention CDC WONDER for 1999–2024, showed increasing rates during the most recent decade. In 2024, the national ASMR was 6.8 per 100,000 (95% CI, 6.7–6.9), including 8.5 (95% CI, 8.4–8.6) in men and 5.5 (95% CI, 5.4–5.6) in women. Using Seasonal Autoregressive Integrated Moving Average (SARIMA) modeling, the national ASMR is projected to increase to 11.93 per 100,000 (95% CI, 7.68–16.17) by 2035, corresponding to a cumulative increase of 75.4% over the forecast period. The average annual percentage change between 2025 and 2035 was 4.98% (95% CI, 1.03–8.86). The forecast trends are shown in Figures 6 and 7. SARIMA Forecast of Overall Age-Standardized Mortality Rates (ASMR) for Heart Failure with Comorbid Hyperlipidemia, United States, 2025–2035. SARIMA Forecast of Age-Standardized Mortality Rates (ASMR) Stratified by Sex for Heart Failure with Comorbid Hyperlipidemia, United States, 2025–2035. Sex-stratified forecasts indicated continued increases in both sexes. Among females, the ASMR is projected to increase from 5.90 per 100,000 in 2025 to 9.87 per 100,000 in 2035 (AAPC, 3.24%; 95% CI, 1.49–5.05). Among males, the ASMR is projected to increase from 9.11 per 100,000 in 2025 to 14.51 per 100,000 in 2035 (AAPC, 4.78%; 95% CI, 1.02–8.70). The male-to-female ASMR ratio was 1.55 in 2024 and is projected to remain elevated until 2035. Wider confidence intervals were observed in later forecast years, indicating greater variability in the projected mortality estimates. 4. Discussion This national analysis of mortality trends from 1999 to 2024 revealed a substantial and sustained increase in deaths related to heart failure and hyperlipidemia in the United States. Overall, age-adjusted mortality rates increased more than ninefold over the 25-year period, with particularly sharp accelerations observed after 2018. The rise was evident across all demographic groups but was consistently higher among men than among women. Marked racial, ethnic, and geographic disparities were identified; mortality rates were highest among American Indian or Alaska Native, non-Hispanic Black, and non-Hispanic White populations in the Western and Midwestern census regions. Furthermore, individuals residing in nonmetropolitan counties experienced persistently higher death rates than those in metropolitan areas, underscoring the widening urban–rural mortality gap. State-level variation was pronounced, with the highest burden concentrated in parts of the Midwest and northern states, such as Vermont and Nebraska, whereas the lowest rates were observed in the Northeast and parts of the South. Collectively, these findings highlight the growing national burden of heart failure and hyperlipidemia–related mortality, with distinct demographic and regional patterns that warrant targeted public health and preventive strategies (Fig. 8). Demographic patterns in age-adjusted mortality rates (AAMR) for hyperlipidemia and heart failure in the United States from 1999 to 2024. We reported that heart failure mortality continuously increased, which was also reported by data published in Circulation in 2013.[20] Collectively, these data suggest that the prevalence of HF varied considerably from 1% to 12%, based largely on United States and European reports, while acute myocardial infarction-related deaths have improved over the past decades.[21] Other heart conditions, such as heart failure and hypertensive heart disease, increased by approximately 13% and 9% in 2018, respectively.[22,23] There is evidence that public and clinical steps have been taken to decrease the risk of various heart diseases, such as smoking, which contributes to as much as 21% of ischemic heart disease mortality.[24] The Joint National Committee issued 8 sets of hypertension guidelines from 1977 to 2014, with sequential lowering of blood pressure goals to reduce the burden of heart disease and its sequelae.[25] Similarly, from 1988 to 2013, cholesterol goals were lowered according to the National Cholesterol Education Program’s guidelines, driving the proportion of adults taking cholesterol lowering medications from 3% in 1988 to approximately 45% in 2013, and subsequently decreasing the mean total cholesterol and low-density lipoprotein levels in the United States.[26] However, despite progress in therapies and guidelines, the prevalence of several heart disease risk factors, such as obesity, diabetes, hypertension, and physical inactivity, has increased in the United States. From the 1970s to 2022, obesity prevalence rose from 15% to 40%,[27] and the demographic shift toward an aging population allows for longer accumulation and thus mortality of heart failure.[28] The rise in mortality observed between 2018 and 2021 coincided with the COVID-19 pandemic. Several mechanisms may explain this temporal association, including disruptions in routine healthcare delivery, delays in seeking medical care, interruptions in chronic disease management, and cardiovascular complications associated with SARS-CoV-2 infection.[29,30] Nevertheless, this analysis relied on death certificate data from the CDC WONDER database, and a portion of the observed increase may also reflect changes in diagnostic recognition, documentation, or death certification practices over time rather than a true rise in the disease burden. Sex-stratified analysis showed consistently higher mortality rates among men than women, which is consistent with published data on sex-based cardiovascular risk disparities.[31] Estrogen is thought to provide cardiovascular protection through its favorable effects on lipid and metabolic profiles, including reductions in LDL cholesterol, lipoprotein(a), homocysteine, and fibrinogen concentrations. Consequently, premenopausal women generally have a lower cardiovascular risk, whereas this protection diminishes after menopause as estrogen concentrations decline, contributing to a greater risk of cardiovascular events.[32] In men, sex hormone concentrations decline more gradually with advancing age rather than undergoing the marked hormonal transition observed during menopause. Testosterone and dehydroepiandrosterone (DHEA) have been associated with favorable lipid effects, including higher HDL cholesterol and lower triglyceride and LDL cholesterol concentrations. The progressive reduction in these hormonal effects with age may therefore contribute to increasing cardiovascular risk among older men.[33] Although several cardiovascular risk factors are shared by both sexes, their relative contributions appear to differ. Advancing age, hypertension, total cholesterol, and LDL cholesterol were reported to have stronger associations with cardiovascular risk in men, whereas smoking, diabetes, triglyceride concentrations, and HDL cholesterol were more influential among women.[34] In particular, elevated LDL cholesterol appears to confer a greater increase in cardiovascular risk among men, while HDL cholesterol may have a comparatively stronger relationship with cardiovascular outcomes in women.[35] Our findings indicate a disproportionate burden among Black and American Indian populations, consistent with prior evidence demonstrating greater exposure to several modifiable HF risk factors in African American, American Indian, and Hispanic communities. These include conditions such as hypertension, obesity, and diabetes, all of which contribute to an increased risk of heart failure.[36] Beyond differences in risk-factor prevalence, social and economic inequities may also contribute to these disparities, consistent with the Healthy People 2020 framework, which characterizes health disparities as differences in health outcomes arising from social or economic disadvantage. African American individuals also experience a greater proportion of HF attributable to nonischemic etiologies. Moreover, although HF incidence generally increases with advancing age, African American patients tend to develop HF at a younger age than White patients.[37] If we look at recent study, they found that AAMR for HF was highest in African American men, followed by non-Hispanic White, American Indian or Alaskan Native, Hispanic, and Asian Pacific Islander men, respectively.[38] Among women, the highest age-adjusted HF death rates were observed in African American women, followed by American Indian women. Despite higher risk factor profiles,[39] Hispanic patients with HF with preserved ejection fraction (HFpEF) have lower mortality than non-Hispanic White patients but a similar mortality risk in HF with reduced EF (HFrEF).[40] Obesity prevalence during 2017-2020 was highest among NH Black adults, followed by Hispanic, non-Hispanic White, and non-Hispanic Asian adults[41] Overall, AAMR was greatest in the Midwest, with the West ranking next. Prior evidence points to elevated heart failure mortality across the South and Midwest, a pattern that aligns with earlier research documenting regional differences in heart failure and stroke death rates. Because these higher rates concentrated in the Southern states, the area came to be known as the “stroke belt.”[42,43] Additional work has shown that heart failure morbidity, as captured through hospitalization, likewise concentrates in Southern and Midwestern states. These geographic and demographic patterns have several contributing causes.[44] Hypertension, obesity, and diabetes mellitus, for example, vary considerably from region to region in how much they contribute to heart failure mortality, which points to room for prevention efforts tailored to the state and local level. Communities outside metropolitan areas differ from metropolitan ones in demographic, environmental, economic, and social respects, and these differences shape both the scale and the nature of the health challenges they encounter. Rates of cigarette smoking, hypertension, obesity, and leisure-time physical inactivity all run higher in nonmetropolitan settings.[45,46] More residents of nonmetropolitan areas lived in poverty than those of metropolitan areas.[47] Obesity in particular is far more prevalent in rural than urban populations: CDC surveillance data from 2016 recorded an obesity rate of 34.2% among adults in rural counties versus 28.7% in metropolitan counties.[48] Even after adjusting for demographics, diet, and physical activity, the prevalence of obesity was still significantly higher in rural populations, suggesting that these differences are multifactorial[49,50] The SARIMA models applied in this study provide robust machine learning–based projections of heart failure and hyperlipidemia-related mortality through 2035, revealing a concerning upward trajectory that may challenge the cardiovascular progress achieved in recent decades. The overall ASMRs are forecasted to reach 11.93 per 100,000 (95% CI: 7.68–16.17) by 2035, representing a 75.4% cumulative increase from 2024 levels, with an average annual percentage change of 4.98% (95% CI: 1.03–8.86%). Sex-specific forecasts indicate persistently higher burdens among males (14.51 per 100,000 by 2035; AAPC 4.78%) than among females (9.87 per 100,000; AAPC 3.24%), while widening prediction intervals in later years highlight the growing uncertainty driven by potential unmodeled shocks such as escalating obesity, diabetes, and health care access disruptions.[35,51] These projections underscore the urgent need for intensified primary prevention and lipid management strategies to mitigate the projected resurgence in cardiovascular mortality. 5. Study limitations Despite its comprehensive national scope, this study has several limitations. First, reliance on death certificate data may introduce misclassification bias, as hyperlipidemia and heart failure may be underreported or inaccurately coded as contributing rather than underlying causes, particularly in elderly, multimorbid patients.[13] Second, ICD-10 coding transitions and changes in certification practices over the 26-year period could have influenced the observed trends.[3] Third, ecological design precludes individual-level risk factor adjustment, limiting causal inference regarding obesity, diabetes, and socioeconomic drivers.[27] Fourth, the suppression of small cell sizes in the CDC WONDER data may reduce precision in sparsely populated states and certain racial/ethnic subgroups, especially American Indian/Alaska Native populations.[15] Fifth, no sensitivity analyses were performed using alternative ICD-10 code sets or case definitions, which limits assessment of the robustness of the primary findings. Sixth, SARIMA models assume the continuation of historical patterns and cannot account for future policy interventions, novel therapies, or unforeseen pandemics, potentially overestimating long-term mortality.[51] 6. Conclusions This 26-year national analysis demonstrated a sustained increase in heart failure–and hyperlipidemia–related mortality in the United States between 1999 and 2024. Mortality rates rose substantially over the study period and are projected to continue increasing through 2035 based on SARIMA forecasts. The burden remains disproportionately higher among men, non-Hispanic Black and American Indian/Alaska Native populations, and residents of nonmetropolitan counties, highlighting the persistent demographic and geographic disparities. These findings emphasize the need for strengthened public health strategies focused on cardiovascular risk reduction, improved lipid management, and equitable access to preventive and clinical care to mitigate the growing burden of heart failure–related mortality. Author contributions Conceptualization: Biruk Demisse Ayalew, David N Smith. Data curation: Biruk Demisse Ayalew, Muhammad Umar, Talha Ali, Sahil Jairamani. Formal analysis: Biruk Demisse Ayalew, Laksh Kumar, Talha Ali, Sahil Jairamani, Adarsh Raja, Ibrahim Khalil. Writing – original draft: Biruk Demisse Ayalew. Writing – review & editing: Biruk Demisse Ayalew, David N Smith, Muhammad Umar, Talha Ali, Sahil Jairamani, Adarsh Raja, Ibrahim Khalil, Mirza Mohammad Ali Baig. Investigation: David N Smith, Muhammad Umar, Adarsh Raja, Ibrahim Khalil. Methodology: David N Smith, Laksh Kumar. Supervision: David N Smith. Validation: David N Smith, Laksh Kumar, Adarsh Raja. Software: Laksh Kumar. Visualization: Laksh Kumar, Muhammad Umar.